PBT-1 Prana Biotechnology.

Name: PBT-1 Prana Biotechnology.
Creator: Richard, Huckle
Keywords: 03 medical and health sciences, Clinical Trials as Topic, 0302 clinical medicine, Amyloid beta-Peptides, Alzheimer Disease, Animals, Humans, Clioquinol, 3. Good health

Richard, Huckle

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2005

Data sources: Europe PubMed Central

PBT-1 Prana Biotechnology.

descriptionPublicationkeyboard_double_arrow_right Article 09 May 2005 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 6 (issn: 1472-4472,

Copyright policy )

Authors: Richard, Huckle;

pmid: 15675609

PBT-1 Prana Biotechnology.

- Summary
- Subjects
- Metrics

Abstract

PBT-1 (clioquinol), is undergoing phase II clinical trials by Prana Biotechnology Ltd for the potential treatment of Alzheimer's disease. By October 2004, the company had planned phase III trials for the first half of 2005.

Keywords

Clinical Trials as Topic, Amyloid beta-Peptides, Alzheimer Disease, Animals, Humans, Clioquinol

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	6
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average